-+ 0.00%
-+ 0.00%
-+ 0.00%

Rhythm Pharma says setmelanotide cuts BMI 18.9% at 2.5 years in hypothalamic obesity study

PUBT·06/15/2026 20:01:25
Listen to the news
Rhythm Pharma says setmelanotide cuts BMI 18.9% at 2.5 years in hypothalamic obesity study
  • Rhythm Pharmaceuticals flagged new clinical updates on its MC4R agonists at ENDO 2026, with results already presented during the meeting.
  • Setmelanotide showed durable weight loss over long-term follow-up in acquired hypothalamic obesity, supporting its potential as a chronic therapy option.
  • Oral bivamelagon produced continued improvements in weight and patient-reported hunger over one year in acquired hypothalamic obesity, reinforcing its oral development strategy.
  • Real-world analyses in Bardet-Biedl syndrome indicated meaningful weight-related benefits with setmelanotide, alongside lower obesity-related outpatient utilization.
  • Additional ENDO posters pointed to benefits in acquired hypothalamic obesity subgroups, including patients with prior bariatric surgery, with separate positive data referenced in Prader-Willi syndrome.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606151601PRIMZONEFULLFEED9747125) on June 15, 2026, and is solely responsible for the information contained therein.